News headlines about Sinovac Biotech (NASDAQ:SVA) have been trending somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sinovac Biotech earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.3486468297357 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Sinovac Biotech (SVA) traded up 0.57% during midday trading on Thursday, hitting $7.11. The stock had a trading volume of 41,558 shares. The company’s market capitalization is $405.04 million. Sinovac Biotech has a one year low of $4.60 and a one year high of $7.16. The firm’s 50-day moving average is $6.91 and its 200 day moving average is $6.19.
Several equities research analysts have recently issued reports on the company. BidaskClub lowered Sinovac Biotech from a “buy” rating to a “hold” rating in a report on Saturday, September 9th. ValuEngine upgraded Sinovac Biotech from a “sell” rating to a “hold” rating in a report on Friday, June 30th.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Sinovac Biotech (SVA) Share Price” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/10/12/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-sinovac-biotech-sva-share-price.html.
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps.
What are top analysts saying about Sinovac Biotech Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sinovac Biotech Ltd. and related companies.